Keywords: Sosei, Vectura, Novartis, Sandoz, QVA149, NVA237, Financial update

Sosei and Vectura get $7.5 million milestone each, as Novartis starts Ph III study with QVA149 and NVA237

Article | 10 May 2010

Print This

Swiss drug major Novartis has commenced a Phase III clinical progam with QVA149, a once-daily, dry powder bronchodilator for inhalation ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in